In this issue:
Leukaemia selection
Chromosomal abnormalities and prognosis in NPM1-mutated AML
Gilteritinib vs. chemotherapy for relapsed/refractory FLT3-mutated AML
Real-world disease progression after ibrutinib discontinuation in CLL
Real-world venetoclax + azacitidine for untreated AML
Undetectable MRD by NGS predicts CLL outcome after FCR
Lymphoma selection
Early progression as survival predictor in marginal zone lymphomas
Early progression after B-R and transformation risk in advanced-stage FL
PET-guided treatment in early-stage favourable Hodgkin’s lymphoma
Nivolumab + brentuximab for relapsed/refractory primary mediastinal large B-cell lymphoma
Obstetric and maternal outcomes in Hodgkin’s lymphoma during pregnancy
Please login below to download this issue (PDF)